End-stage renal disease in a bodybuilder: a multifactorial process or simply doping?
Hartung
R
R
Department of Internal Medicine IV, Friedrich-Schiller-University of Jena, Germany.
Gerth
J
J
Fünfstück
R
R
Gröne
H J
HJ
Stein
G
G
D000318:Adrenergic beta-Agonists / Q000009:adverse effects; D000328:Adult; D045930:Anabolic Agents / Q000009:adverse effects; D002976:Clenbuterol / Q000008:administration & dosage; D004300:Doping in Sports; D015444:Exercise; D006801:Humans; D007676:Kidney Failure, Chronic / Q000209:etiology* / Q000473:pathology; D008297:Male; D012307:Risk Factors
D000318:Adrenergic beta-Agonists; D045930:Anabolic Agents; D002976:Clenbuterol